Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

UNLEASH

Financiado

Harnessing the splicing code for targeted control of gene expression

Alternative splicing (AS) of mRNA precursors plays important roles in tissue-specific gene regulation and biological regulatory mechanisms, as it can radically alter protein expression, cell phenotypes and physiological responses.... ver más

31/05/2029

FUNDACIO PRIVADA C...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 50K€

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-02

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-SyG: ERC Synergy Grants

I+D

Cerrada hace 3 años

0% 100% 100%

3 Participantes

FUNDACIO PRIVADA CENTRE DE R...

2.50M€ | Lider

HMGU

2.50M€ | Participante

UNIVDUN

N.D. | Participante

Proyectos interesantes

BFU2014-54660-R ACOPLAMIENTO FUNCIONAL ENTRE LA TRANSCRIPCION Y EL SPLICING 169K€ Cerrado

MASCP Mechanisms of alternative pre mRNA splicing regulation in ca... 2M€ Cerrado

BFU2011-25697 BASES MOLECULARES DEL SPLICING DE PRE-MRNA 247K€ Cerrado

BFU2008-00363 MECANISMOS MOLECULARES INVOLUCRADOS EN EL CONTROL DEL SPLICI... 25K€ Cerrado

BFU2017-84492-R PROTEINAS DE INTERACCION CON RNA IMPLICADAS EN EL CONTROL PO... 183K€ Cerrado

BFU2008-03558 MECANISMOS DE REGULACION DEL PROCESAMIENTO ALTERNATIVO DE PR... 501K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 74 meses Fecha Inicio: 2023-03-02
Fecha Fin: 2029-05-31

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA

TRL 4-5 | 50K€

Presupuesto del proyecto 5M€

Descripción del proyecto Alternative splicing (AS) of mRNA precursors plays important roles in tissue-specific gene regulation and biological regulatory mechanisms, as it can radically alter protein expression, cell phenotypes and physiological responses. Altered splicing also contributes to disease mechanisms, ranging from neurodegeneration to cancer. Drugs modulating AS have recently provided the first therapy for Spinal Muscular Atrophy, a common genetic disorder, illustrating the huge potential for treating many other diseases of unmet need, if only we understood the mechanisms controlling splice site selection and how to regulate them with small molecules. Unfortunately, despite decades of research, a comprehensive understanding of the mechanisms that control specificity of AS is lacking. This gap in basic knowledge prevents opportunities to harness splicing modulators as tools to study gene function, novel therapeutics or other biotech applications. This Project addresses head-on the major technical challenges that have limited progress in the AS field. Building on extensive preliminary data, we will use a multidisciplinary approach that combines chemical, structural, cellular, systems biology and machine learning to characterize mechanisms of splice site selection and identify targets for modulating these mechanisms using tool compounds. The outcomes will define key regulatory sequences, splicing factors and molecular interactions involved, thereby illuminating how the splicing machinery efficiently accommodates, yet also discriminates between, a wide range of splice site sequences. This will enable future applications harnessing splice site selection. Our primary goal is to answer the central question, ‘Is it generally possible to modulate splicing with high specificity using small molecules?’ Success will transform our basic understanding of human gene expression and unleash major opportunities for Pharma to develop new therapeutics.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores